Hana Pharm하나제약
293480 · KOSPI · ₩293480 · 하나제약
₩8,170▼ ₩40 (0.49%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩240B | ₩225B | ₩224B | ₩211B | ₩196B |
| Cost of sales | ₩95B | ₩84B | ₩85B | ₩80B | ₩66B |
| Gross profit | ₩145B | ₩141B | ₩140B | ₩131B | ₩131B |
| Operating income | ₩26B | ₩25B | ₩27B | ₩31B | ₩36B |
| Net income | ₩8.8B | ₩21B | ₩22B | ₩24B | ₩28B |
| Net income to shareholders | ₩8.8B | ₩21B | ₩22B | ₩24B | ₩28B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩418B | ₩382B | ₩348B | ₩346B | ₩303B |
| Current assets | ₩118B | ₩106B | ₩102B | ₩104B | ₩140B |
| Cash and equivalents | ₩9.8B | ₩8.5B | ₩1.4B | ₩13B | ₩6.6B |
| Total liabilities | ₩105B | ₩73B | ₩70B | ₩78B | ₩52B |
| Current liabilities | ₩64B | ₩32B | ₩56B | ₩45B | ₩41B |
| Borrowings | ₩56B | ₩27B | ₩23B | ₩30B | ₩8.4B |
| Total equity | ₩313B | ₩309B | ₩278B | ₩268B | ₩252B |
| Shareholders' equity | ₩313B | ₩309B | ₩278B | ₩268B | ₩252B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩9.2B | ₩25B | ₩18B | ₩31B | ₩26B |
| Free cash flow | ₩9.2B | ₩25B | ₩18B | ₩31B | ₩26B |
| Dividends paid | ₩8.8B | ₩8.8B | ₩8.8B | ₩8.8B | ₩8B |
Consolidated where available. Amounts in won.
Also known as: Hana Pharm / 하나제약 / 293480 / KRX:293480
Source: KRX statistical information